EUVIMEDOpdag EUVIMED
Crossref

Identification of a novel inhibitor of SARS‐CoV ‐2 main protease: an in silico , biochemical, and cell‐based approach

Aditya Trivedi iD, Vandana Kardam iD, Krishna Kishore Inampudi, Sudhanshu Vrati, Dharmender Gupta, Aekagra Singh iD, Sarala Rani Kayampeta, Mohan Babu Appaiahgari iD, Deepak Sehgal iD

The FEBS Journal · 2023

DOI: 10.1111/febs.16947 ↗

At a glance

Journal article in The FEBS Journal, 2023. Written by Aditya Trivedi and 8 co-authors. Institution: Department of Life Sciences, School of Natural Sciences, Shiv Nadar Institution of Eminence, Greater Noida, Uttar Pradesh, India. Major MEDLINE topics: COVID-19. Cited 7 times so far (Crossref); 63 references. Funded by: Biotechnology Industry Research Assistance Council, DBT-Ramalingaswami, Department of Biotechnology, Ministry of Science and Technology, India.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

The recurrent nature of coronavirus outbreaks, severity of the COVID‐19 pandemic, rapid emergence of novel variants, and concerns over the effectiveness of existing vaccines against novel variants have highlighted the need to develop therapeutic interventions. Targeted efforts to identify inhibitors of crucial viral proteins are the preferred strategy. In this study, we screened FDA‐approved and natural product libraries using in silico approach for potential hits against the SARS‐CoV‐2 main protease (Mpro) and experimentally validated their potency using in vitro biochemical and cell‐based assays. Seven potential hits were identified through in silico screening and were subsequently evaluated in SARS‐CoV‐2‐based cell‐free assays, followed by testing in the HCoV‐229E‐based culture system. Of the tested compounds, 4‐(3,4‐dihydroxyphenyl)‐6,7‐dihydroxy‐1‐isopropyl‐1H‐benzofuro[3,2‐b]pyrazolo[4,3‐e]pyridin‐3(2H)‐one (PubChem CID:71755304, hereafter referred to as STL522228) exhibited significant antiviral activity. Subsequently, its potential as a novel COVID therapeutic molecule was validated in the SARS‐CoV‐2‐culture system, where STL522228 demonstrated superior antiviral activity (EC 50 = 0.44 μ m ) compared to Remdesivir (EC 50 = 0.62 μ m ). Based on these findings, we report the strong anti‐coronavirus activity of STL522228, and propose that it as a promising pan‐ coronavirus Mpro inhibitor for further experimental and preclinical validation.

Subjects

MeSH terms (MEDLINE)

COVID-19HumansSARS-CoV-2PandemicsAntiviral AgentsProtease InhibitorsMolecular Docking SimulationCoronavirus 3C Proteases

Author keywords

in silicoHCoV-229EMproSARS-CoV-2STL522228coronavirus

Substances

Antiviral AgentsProtease Inhibitors3C-like proteinase, SARS-CoV-2Coronavirus 3C Proteases

Authors and institutions

  • Department of Life Sciences, School of Natural Sciences, Shiv Nadar Institution of Eminence, Greater Noida, Uttar Pradesh, India.
  • Department of Chemistry, School of Natural Sciences, Shiv Nadar Institution of Eminence, Greater Noida, Uttar Pradesh, India.
  • Department of Biophysics, All India Institute of Medical Sciences, New Delhi, India.
  • Laboratory of Virology, Regional Centre for Biotechnology, NCR Biotech Science Cluster, Faridabad, India.
  • Research and Development Division, Srikara Biologicals Private Limited, Tirupati, India.

ORCID profiles: Aditya Trivedi, Vandana Kardam, Aekagra Singh, Mohan Babu Appaiahgari, Deepak Sehgal

Funding

  • Biotechnology Industry Research Assistance Council
  • DBT-Ramalingaswami
  • Department of Biotechnology, Ministry of Science and Technology, India
  • Indian Council of Medical Research
  • Science and Engineering Research Board
  • Department of Biotechnology, Government of West Bengal

Cite

APA

Trivedi, A., Kardam, V., Inampudi, K. K., Vrati, S., Gupta, D., Singh, A., Kayampeta, S. R., Appaiahgari, M. B., & Sehgal, D. (2023). Identification of a novel inhibitor of SARS‐CoV ‐2 main protease: an in silico , biochemical, and cell‐based approach. The FEBS Journal. https://doi.org/10.1111/febs.16947

Vancouver

Trivedi A, Kardam V, Inampudi KK, Vrati S, Gupta D, Singh A, et al. Identification of a novel inhibitor of SARS‐CoV ‐2 main protease: an in silico , biochemical, and cell‐based approach. The FEBS Journal. 2023. doi:10.1111/febs.16947

BibTeX
@article{Trivedi2023,
  author = {Trivedi, Aditya and Kardam, Vandana and Inampudi, Krishna Kishore and Vrati, Sudhanshu and Gupta, Dharmender and Singh, Aekagra and Kayampeta, Sarala Rani and Appaiahgari, Mohan Babu and Sehgal, Deepak},
  title = {Identification of a novel inhibitor of SARS‐CoV ‐2 main protease: an in silico , biochemical, and cell‐based approach},
  journal = {The FEBS Journal},
  year = {2023},
  doi = {10.1111/febs.16947}
}
Start for free →